News & insights
Keytruda
Articles from Apotek Analytics.
-

Lilly’s retatrutide beats Ozempic. Artiva drops its autoimmune cell therapy after two trial deaths
Eli Lilly’s ‘triple-G’ drug retatrutide beat Novo Nordisk’s Ozempic on blood sugar and weight loss in a head-to-head phase 3 trial in type 2 diabetes, though with more side effects and treatment discontinuations.
-

FDA approves GSK and Ionis hepatitis B drug that offers some patients a functional cure
The FDA approved bepirovirsen, a first of its kind antisense injection for chronic hepatitis B from GSK and Ionis, as dealmaking led the rest of the week’s coverage.